Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on Jan 24, 2021 5:40pm
225 Views
Post# 32371833

RE:New Insider Buys

RE:New Insider Buys
Amended Filing Amended FilingAs of 11:59pm ET January 24th, 2021
Filing
Date Transaction
Date Insider Name Ownership
Type Securities Nature of transaction Volume or Value Price
Jan 24/21 Jan 19/21 Lvesque, Paul Direct Ownership Warrants 15 - Acquisition under a prospectus 20,000 $0.220
USD
Jan 24/21 Jan 19/21 Lvesque, Paul Direct Ownership Common Shares 15 - Acquisition under a prospectus 40,000 $2.53
USD
Jan 24/21 Jan 19/21 Pommier, Paul Direct Ownership Warrants 15 - Acquisition under a prospectus 15,000 $0.220
USD
Jan 24/21 Jan 19/21 Pommier, Paul Direct Ownership Common Shares 15 - Acquisition under a prospectus 30,000 $2.53
USD
Jan 21/21 Jan 19/21 Dubuc, Philippe Direct Ownership Warrants 15 - Acquisition under a prospectus 1,500 $0.440
USD
Jan 21/21 Jan 19/21 Dubuc, Philippe Direct Ownership Common Shares 15 - Acquisition under a prospectus 3,000 $2.53
USD
Jan 21/21 Jan 19/21 Trudeau, Alain Direct Ownership Warrants 15 - Acquisition under a prospectus 2,500 $0.440
USD
Jan 21/21 Jan 19/21 Trudeau, Alain Direct Ownership Common Shares 15 - Acquisition under a prospectus 5,000 $2.53
USD


realitycheck4u wrote: This does not get any better than this.

Paul Levesque bought 40,000 shares in the financing 
Paul Pommier bought 30,000 share too!


<< Previous
Bullboard Posts
Next >>